Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

202.42
-0.9350-0.46%
Volume:666.33K
Turnover:134.04M
Market Cap:43.38B
PE:-22.69
High:206.36
Open:204.98
Low:197.81
Close:203.35
52wk High:224.31
52wk Low:42.18
Shares:214.34M
Float Shares:185.00M
Volume Ratio:1.18
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.65
PE(LYR):-34.02

Loading ...

Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million

Reuters
·
Yesterday

Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.

Dow Jones
·
Yesterday

Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says

MT Newswires Live
·
Sep 10

Morgan Stanley Initiates Coverage on Revolution Medicines With Overweight Rating

MT Newswires Live
·
Sep 10

Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255

THOMSON REUTERS
·
Sep 10

BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion

Reuters
·
Sep 10

Revolution Medicines Price Target Raised to $230.00/Share from $215.00 by Stifel

Dow Jones
·
Sep 09

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Sep 09

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)

TIPRANKS
·
Sep 03

Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target

TIPRANKS
·
Sep 03

NEJM publishes Phase 1/2 clinical data on daraxonrasib

TIPRANKS
·
Sep 03

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

GlobeNewswire
·
Sep 03

Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million

Reuters
·
Sep 03

J.P. Morgan Sticks to Their Buy Rating for Revolution Medicines (RVMD)

TIPRANKS
·
Sep 02

Revolution Medicines Signs Long-Term Headquarters Lease Agreement

TIPRANKS
·
Sep 01

Revolution Medicines (RVMD) Could Be 7% Below Fair Value On FDA Approval Of RASONQUE

Simply Wall St.
·
Sep 01

Revolution Medicines is Maintained at Buy by Needham

Dow Jones
·
Aug 31

Ami Fadia Raises RVMD Price Target to $275 on Strong Rasonque U.S. Launch Economics and Robust Oncology Pipeline

TIPRANKS
·
Aug 31

Revolution Medicines, Inc. : Needham Raises Target Price to $275 from $240

THOMSON REUTERS
·
Aug 31

U.S. Research Roundup-Adobe, Braveheart Bio, CACI International

Reuters
·
Aug 31